Skip to main content
Premium Trial:

Request an Annual Quote

Harvard Bio Q2 Revenues Drop 3.3 Percent, Net Loss Surges on Charges

NEW YORK, Aug. 9 (GenomeWeb News) - Harvard Bioscience, which recently announced that it would divest its capital equipment business, today reported second quarter revenue of $21.7 million, a 3.3 percent drop from revenue of $22.5 million in last year's second quarter.

 

The firm's apparatus and instrumentation unit, which it is retaining, brought in revenue of $16.3 million for the quarter, up 4.2 percent year over year from $15.6 million. Revenue for the capital equipment segment dropped a sharp 20.3 percent to $5.4 million from $6.8 million in last year's second quarter.

 

Harvard Bio posted a net loss of $27.4 million, or $.90 per share, compared with a net profit of $298,000, or $.01 per share, year over year. The loss includes asset abandonment and impairment charges of $17.9 million related to the divestiture of the capital equipment business.

 

The firm also disclosed that it has hired investment banking firm Thomas Weisel Partners to help it find a buyer for the capital equipment segment, which includes the Genomic Solutions business. The company said it would use proceeds from the sale to pay down its $15.2 million debt facility and finance tuck-in acquisitions.

 

As of June 30, Harvard Bio had cash and cash equivalents of $13.2 million.

The Scan

Should've Been Spotted Sooner

Scientists tell the Guardian that SARS-CoV-2 testing issues at a UK lab should have been noticed earlier.

For Martian Fuel

Researchers have outlined a plan to produce rocket fuel on Mars that uses a combination of sunlight, carbon dioxide, frozen water, cyanobacteria, and engineered E. coli, according to Gizmodo.

To Boost Rapid Testing

The Washington Post writes that new US programs aim to boost the availability of rapid at-home SARS-CoV-2 tests.

PNAS Papers on Strawberry Evolution, Cell Cycle Regulators, False-Positive Triplex Gene Editing

In PNAS this week: strawberry pan-genome, cell cycle-related roles for MDM2 and MDMX, and more.